亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Safety and early efficacy results from a phase 1, multicenter trial of PSMA-targeted armored CAR T cells in patients with advanced mCRPC.

医学 内科学 细胞因子释放综合征 环磷酰胺 肿瘤科 癌症 胃肠病学 嵌合抗原受体 化疗 免疫疗法
作者
Meredith Ann McKean,Matthew H. Carabasi,Mark N. Stein,Michael Thomas Schweizer,Jason J. Luke,Vivek Narayan,Rahul Atul Parikh,Russell Kent Pachynski,Jingsong Zhang,Vijay G. R. Peddareddigari,James Winnberg,Amy Roberts,Jamie Rosen,Pam Hufner,Whitney Lynn Gladney,Thomas J. Fountaine,Karen Chagin
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:40 (6_suppl): 94-94 被引量:29
标识
DOI:10.1200/jco.2022.40.6_suppl.094
摘要

94 Background: CART-PSMA-02 is a multi-center, open-label, phase 1 trial evaluating the safety and feasibility of CART-PSMA-TGFβRDN T-cells (PSMA-CART) in patients (pts) with metastatic castration resistant prostate cancer (mCRPC). PSMA-CART are engineered to express a chimeric antigen receptor with specificity to PSMA and a dominant negative form of TGFβRII which renders PSMA-CART resistant to TGFβ-mediated immunosuppression. Herein, preliminary safety and efficacy results from this trial are reported. Methods: This is a 3+3 dose escalation study to determine the recommended phase 2 dose and schedule of PSMA-CART cells following lymphodepleting chemotherapy (LD) with cyclophosphamide and fludarabine. Results: As of October 2021, 9 pts were dosed. Two pts received 1-3x107 cells, 4 pts received 1-3x108 cells, and 3 pts received 0.7-1x108 cells with anakinra prophylaxis. Grade 1-2 CRS was observed in all pts receiving 1-3x108 cells and 2/3 pts who received anakinra prophylaxis. No pts developed CRS > G2. Two events of immune-effector cell associated neurotoxicity syndrome (ICANS) were observed (1 G2, 1 G5). Two pts experienced DLTs at dose level of 1-3x108, one of whom developed G5 events of ICANS and multi-organ failure (MOF) after receiving 30% of his fractionated dose (total dose = 0.9x108). This pt’s clinical course and autopsy findings were consistent with macrophage activation syndrome. The trial continued with a modified dose of 0.7-1x108 and the incorporation of prophylactic anakinra (100mg SC daily x7 doses). Another G5 event was observed, likely related to immune toxicity, with ferritin levels peaking at >100,000 ng/mL prior to death. Cause of death on autopsy was equivocal and contributing factors included metastatic prostate cancer, MOF and coagulopathy. Cytokine levels from both pts experiencing G5 events were elevated compared to all other pts (e.g., IL-6, sIL2RA, MIG/CXCL9, MIP1b/CCL4, IP-10/CXCL19, IL2 and IL1b). In pts receiving ≥ 0.9x108 cells (n=7), preliminary efficacy results demonstrated stable disease by RECIST v1.1 at day 28 (D28) in 4/5 evaluable pts. Decreases in serum PSA occurred in 4/7 pts with >50% decreases observed in 2/5 evaluable pts at D28. Conclusions: PSMA-CART has shown preliminary evidence of biological activity in the absence of clear indications of on-target/off-tumor toxicity. The exact mechanisms driving the severe immune-mediated toxicities in this study are currently unclear. While this study has been closed to further enrollment, ongoing research efforts are aimed at exploring patient specific factors, tumor microenvironment factors, and the PSMA-CART construct (including both functional components and armored modules) to design future constructs of PSMA-CART that will enhance the efficacy/safety profile and allow for continued study of this novel therapy in the clinic. Clinical trial information: NCT04227275.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小豆爱科研完成签到,获得积分10
1秒前
魔幻荧完成签到,获得积分10
10秒前
OK的应助被369ninja采纳,获得200
11秒前
Lucas的应助被369ninja采纳,获得10
27秒前
orixero的应助被369ninja采纳,获得10
42秒前
48秒前
努力努力再努力完成签到,获得积分10
56秒前
情怀的应助被369ninja采纳,获得10
57秒前
直率的宛丝完成签到,获得积分10
1分钟前
humorlife完成签到,获得积分10
1分钟前
现代的冰海完成签到,获得积分10
1分钟前
1分钟前
zyyicu完成签到,获得积分10
1分钟前
希望天下0贩的0的应助被369ninja采纳,获得10
1分钟前
霸气惜文完成签到,获得积分10
1分钟前
大模型的应助被369ninja采纳,获得10
1分钟前
1分钟前
369ninja发布了新的文献求助10
1分钟前
懦弱的代云完成签到,获得积分10
1分钟前
如意涵雁完成签到,获得积分10
1分钟前
华仔的应助被爱学习的doge采纳,获得10
1分钟前
英姑的应助被爱学习的doge采纳,获得10
2分钟前
2分钟前
2分钟前
2分钟前
2分钟前
2分钟前
2分钟前
韩_发布了新的文献求助10
2分钟前
彭于晏的应助被科研通管家采纳,获得10
2分钟前
充电宝的应助被sun采纳,获得10
2分钟前
2分钟前
甜甜的文轩完成签到,获得积分10
2分钟前
爱笑的芝麻完成签到,获得积分10
2分钟前
阿双完成签到,获得积分10
2分钟前
sun发布了新的文献求助10
2分钟前
2分钟前
3分钟前
灵巧的绮琴完成签到,获得积分10
3分钟前
整齐的天问完成签到,获得积分10
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179956
求助须知:如何正确求助?哪些是违规求助? 9570170
关于积分的说明 21808444
捐赠科研通 7775818
什么是DOI,文献DOI怎么找? 3433251
关于科研通互助平台的介绍 2557352
邀请新用户注册赠送积分活动 2478958